Fennec Pharmaceuticals Inc. Common Stock
FENCFennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare and life-threatening pediatric diseases. The company's lead candidate, seek to address unmet medical needs by advancing therapies that improve patient outcomes in areas such as oncology and pain management.
Company News
Southpoint Capital Advisors sold 1 million common shares (2.93%) of Fennec Pharmaceuticals on December 24, 2025, at USD $7.50 per share. The firm retains control of 2.7 million shares (approximately 8% of outstanding shares on a fully diluted basis) and may adjust its position based on market conditions.
Fennec Pharmaceuticals plans to raise up to $5,025,000 through a non-brokered offering of common shares in Canada at $7.50 per share, with the offering expected to close on November 17, 2025.
Fennec Pharmaceuticals is conducting a public offering of 4,666,667 common shares at $7.50 per share, expecting to raise approximately $35 million. The proceeds will be used to repurchase debt and for general corporate purposes.
Fennec Pharmaceuticals reported strong Q2 2025 earnings with $9.7 million in net product sales, representing 33% year-over-year growth. The company is expanding internationally through partnerships, securing formulary wins, and preparing for potential milestone events in Europe and Japan.
Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.
